Literature DB >> 24024896

ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.

Tarek Magdy1, Rudolf Arlanov, Stefan Winter, Thomas Lang, Kathrin Klein, Yu Toyoda, Toshihisa Ishikawa, Matthias Schwab, Ulrich M Zanger.   

Abstract

AIM: Because 5-fluorodeoxyuridine monophosphate (5-FdUMP), an anabolic active metabolite of 5-fluorouracil (5-FU), is a substrate of MRP8 (encoded by ABCC11), we investigated whether ABCC11 polymorphisms play a role in severe toxicity of 5-FU. PATIENTS &
METHODS: Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs. Functional impact of polymorphisms was assessed in a Caucasian human liver cohort (n = 150) and by recombinant expression of MRP8 protein variants.
RESULTS: Univariate and multivariate analysis identified rs17822471 (G>A, T546M) as risk factor of severe leukopenia (p = 0.021, odds ratio [95%CI]: 3.31 [1.26-8.66]) but not of other toxicity types. MRP8 protein expression in human liver was 1.7-fold lower in carriers compared with wild-type (p = 0.02). Recombinant expression confirmed the effect of T546M on protein expression.
CONCLUSION: Since MRP8 is expressed in bone marrow blasts and leukocytes, lower expression may lead to intracellular accumulation of 5-FdUMP and increased risk of leukopenia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24024896     DOI: 10.2217/pgs.13.139

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  6 in total

1.  Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant.

Authors:  R Arlanov; T Lang; G Jedlitschky; E Schaeffeler; T Ishikawa; M Schwab; A T Nies
Journal:  Pharmacogenomics J       Date:  2015-04-21       Impact factor: 3.550

2.  The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Authors:  S Hamzic; N Wenger; T K Froehlich; M Joerger; S Aebi; C R Largiadèr; U Amstutz
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

Review 3.  Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.

Authors:  Tarek Magdy; Paul W Burridge
Journal:  Pharmacogenomics       Date:  2021-01-15       Impact factor: 2.533

Review 4.  Diagnosis of Human Axillary Osmidrosis by Genotyping of the Human ABCC11 Gene: Clinical Practice and Basic Scientific Evidence.

Authors:  Yu Toyoda; Tsuneaki Gomi; Hiroshi Nakagawa; Makoto Nagakura; Toshihisa Ishikawa
Journal:  Biomed Res Int       Date:  2016-02-23       Impact factor: 3.411

5.  Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Authors:  Marina Borro; Andrea Botticelli; Federica Mazzuca; Elisa Concetta Onesti; Giovanna Gentile; Adriana Romiti; Bruna Cerbelli; Eva Mazzotti; Luca Marchetti; Luana Lionetto; Maurizio Simmaco; Paolo Marchetti
Journal:  Oncotarget       Date:  2017-02-21

Review 6.  The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?

Authors:  Ana Rita Simões; Ceres Fernández-Rozadilla; Olalla Maroñas; Ángel Carracedo
Journal:  J Pers Med       Date:  2020-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.